Amgen Launches AMGEVITA ™ (Biosimilar Adalimumab) In Markets Across Europe
First Inflammation Biosimilar From Amgen's Portfolio to Launch in Europe
THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS;...
Source: Amgen News Release - October 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves KYPROLIS ® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Approval of a More Convenient Once-Weekly Kd70 Regimen Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study
Application Granted Priority Review Designation
Application Reviewed and Approved Under FDA's Real-Time Oncology Review and Assessment Aid Pilot Programs
THOUSAND OAKS, Calif., Oct. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd...
Source: Amgen News Release - October 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
BLINCYTO ® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
First Approved Oncology Treatment From Amgen Astellas Joint Venture
BLINCYTO is the First-and-Only Approved CD19-Directed CD3 Bispecific T Cell Engager (BiTE®) Immunotherapy
THOUSAND OAKS, Calif., Sept. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). BLINCYTO was developed in Japan by Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical compan...
Source: Amgen News Release - September 25, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA
Amgen's David Piacquad to Join BioLA Board of Directors
THOUSAND OAKS, Calif. and LOS ANGELES, Sept. 20, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the County of Los Angeles today announced that Amgen has agreed to become a founding sponsor of BioLA, a newly formed organization focused on advancing a life science innovation hub in Los Angeles County. The innovation hub is designed to contribute to advancements in global health by strengthening the County's life sciences ecosystem and accelerating the pace of startup activity. BioLA will also focus on creating jobs, driving economic development and promoting the Cou...
Source: Amgen News Release - September 20, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime
From a Sample of Over 10,000 Adults, 62 Percent are Worried They may Develop Alzheimer's Disease and 91 Percent Believe the Solution to Tackling Diseases Lies in Medical Research(1)
79 Percent are Willing to Take Part in Medical Research, but Three-Quarters (75 Percent) Have no Idea how to get Involved(1)
This World Alzheimer's Month, in Association With Alzheimer's Disease International, Amgen, Novartis and Banner Alzheimer's Institute are Raising Awareness About how to get Involved in Alzheimer's Research
THOUSAND OAKS, Calif., Sept. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's ...
Source: Amgen News Release - September 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
THOUSAND OAKS, Calif., Sept. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018, in London. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patie...
Source: Amgen News Release - September 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Morgan Stanley Global Healthcare Conference
THOUSAND OAKS, Calif., Sept. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on Wednesday, Sept. 12, 2018, in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering ...
Source: Amgen News Release - September 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
Designation Supported by Phase 2b PATHWAY Data That Demonstrated Tezepelumab Significantly Reduced Asthma Exacerbations Compared to Placebo in Severe Asthma Patients
THOUSAND OAKS, Calif., Sept. 6, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.
A Breakthrough Therapy Designation is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition and...
Source: Amgen News Release - September 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And LabCentral Open Nomination Process For Lab Residency
An Opportunity for Start-Ups to be Awarded a Golden Ticket
CAMBRIDGE, Mass., Sept. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies. LabCentral is an innovative, shared laboratory space designed as a launchpad for premier high-impact life sciences and biotech startups. As one of LabCentral's platinum sponsors, Amgen can nominate up to two early-stage companies each year to take up residence in LabCentral's Kendall Square fac...
Source: Amgen News Release - September 5, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
European Commission Approves BLINCYTO ® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Approval Based on Data From the Phase 1/2 '205 Study
THOUSAND OAKS, Calif., Aug. 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) as monotherapy for the treatment of pediatric patients aged one year or older with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL), which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. The approval is based on results...
Source: Amgen News Release - August 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Submits Supplemental New Drug Application For KYPROLIS ® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Filing Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study
THOUSAND OAKS, Calif., Aug. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (Kd) for patients with relapsed or refractory multiple myeloma. The sNDA is based on data from the Phase 3 A.R.R.O.W. trial, demonstrating KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-weekly Kd) ach...
Source: Amgen News Release - August 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha ® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018
New Research Evaluates the Benefit of LDL-C Lowering With Repatha Across Gender and Age
Data Assesses the Financial Burden for Patients in Europe With Atherosclerotic Cardiovascular Disease
THOUSAND OAKS, Calif., Aug. 21, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the upcoming presentation of new Repatha® (evolocumab) analyses, including a late-breaking study evaluating the efficacy of Repatha in patients with metabolic syndrome and established cardiovascular disease at the ESC Congress 2018, organized by the European Society of Cardiology, in Munich, Aug. 25-29.
Six abstracts, including two ana...
Source: Amgen News Release - August 21, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island
The Plant Will be First-of-its-Kind in the U.S.
THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets.
"Biologics manufacturing is a complex science and has long been a competitive advantage for Amgen," said Robert A. Bradway, chairman and chief executi...
Source: Amgen News Release - July 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces 2018 Third Quarter Dividend
THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the third quarter of 2018. The dividend will be paid on Sept. 7, 2018, to all stockholders of record as of the close of business on Aug. 17, 2018.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand...
Source: Amgen News Release - July 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Succession Plans For Two Executive Officers
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today.
After more than 21 years of leadership in the biopharmaceutical industry, including the past 16 years with Amgen, Sean E. Harper, M.D., executive vice president of Research and Development, has decided to retire and plans to pursue opportunities in the early-stage biotechnology community. David M. Reese, M.D., currently senior vice president of Translational Sciences and Oncology at Amgen,...
Source: Amgen News Release - July 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
